Leerink Partners Lowers Repligen Earnings Forecast: What Investors Need to Know
Leading equities research firm Leerink Partners recently made waves in the biotechnology sector by revising its earnings per share estimates downward for Repligen Corporation (NASDAQ:RGEN), a move…
William Blair Boosts Repligen’s FY2025 EPS Estimates: What Investors Need to Know
William Blair, a prominent financial analysis firm, recently revised its earnings per share (EPS) estimates for Repligen Corporation, a leading biotechnology company listed on NASDAQ under the…
William Blair Lifts Repligen’s FY2025 EPS Estimates: What Investors Need to Know
In a significant development for the biotechnology sector, leading equities research firm William Blair has revised its earnings per share (EPS) estimates for Repligen Corporation, signaling a…
Leerink Partners Boosts Repligen Earnings Forecast: Biotech Stock Outlook
The biotechnology sector is abuzz with the latest financial projections for Repligen Corporation, as leading investment analysts at Leerink Partners have revised their earnings estimates upward for…